Phase 3 Immunology & Autoimmune Deal Benchmarks

Median Upfront

$766M

Range: $482M - $1.0B

Total Deal Value

$3.0B

Range: $2.1B - $3.8B

Royalty Rate

17.5% - 27.4%

Tiered up to 31.4%

Dev Milestones

$221M

Range: $166M - $280M

Model Your Deal

Market Analysis

Phase 3 immunology & autoimmune licensing deals carry a median total deal value of $3.0B, with upfront payments ranging from $482M to $1.0B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 26% to upfront and 74% to milestones.

The immunology & autoimmune landscape at the phase 3 stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $221M, regulatory milestones contribute $662M, and commercial milestones reach $1.3B. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.

Royalty rates for phase 3 immunology & autoimmune deals range from 17.5% to 27.4% at the base tier, with high-tier escalation to 31.4%. The reduced risk profile at this stage justifies higher fixed royalty commitments.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 3 immunology & autoimmune deals?

Phase 3 immunology & autoimmune deals average $766M in upfront payments, ranging from $482M to $1.0B. The upfront allocation of 26% of total deal value reflects the clinical stage risk profile.

How are phase 3 immunology & autoimmune deal milestones structured?

Milestones account for approximately 74% of total deal value. Development milestones ($221M) represent the largest component, followed by commercial milestones ($1.3B) and regulatory milestones ($662M).

What royalty rates are typical for phase 3 immunology & autoimmune licensing?

Base royalty rates range from 17.5% to 27.4%, with tiered escalation to 21.5%-31.4% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 3 Immunology & Autoimmune Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Preclinical Immunology & Autoimmune Deals

Phase 1 Immunology & Autoimmune Deals

Phase 3 Oncology Deals

Phase 3 Neurology Deals

Ready to Calculate Your Deal Terms?